High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Intuitive Surgical (ISRG) has been one of the year’s most punished large-cap healthcare names. The maker of the da Vinci surgical robot has watched its stock fall about 28% in 2026, even as revenue keeps climbing. Analysts have piled on. Deutsche Bank slashed its target. Bank of America trimmed its ...
While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. Inquiring about the stock, a caller asked if it is a buy. Cramer replied: Too much competition, too much competition… Used to be king, […]
ISRG raises its 2026 outlook after strong Q1 results, but can broad-based procedure growth offset emerging headwinds in key U.S. and global markets?
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]
With a short percentage of shares outstanding of 2.05%, Intuitive Surgical, Inc. (NASDAQ:ISRG) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 2, Deutsche Bank reduced its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 while maintaining a Sell rating on the shares. The revised target reflects the firm’s updated valuation outlook for the […]
In late May, Intuitive Surgical announced leadership changes effective July 1, promoting nearly 20-year company veteran Taylor Patton to Chief Commercial and Marketing Officer while moving current CCMO Henry Charlton into a new Senior Vice President of Global Business Operations role focused on global value generation. These executive moves come as Intuitive manages FDA safety alerts, product recalls, and rising competition, all while relying on its large installed da Vinci base and...
If you are wondering whether Intuitive Surgical stock is starting to offer better value or still pricing in a lot of optimism, you are not alone. The share price closed at US$406.78, with returns declining 2.3% over the past week, 7.1% over the past month, and 27.6% year to date. The return over the past 1 year is down 21.0% and the 3 and 5 year returns are 25.1% and 33.7% respectively. Recent coverage has focused on how Intuitive Surgical sits within medical technology and minimally...
Intuitive Surgical (ISRG) is back in focus after recent trading data showed the stock down about 7% over the past month and around 14% over the past 3 months, sharpening attention on its long term track record. See our latest analysis for Intuitive Surgical. At a share price of $406.78, Intuitive Surgical’s recent 1 month share price return of about 7% down and year to date share price return of about 28% down point to fading short term momentum, even though the 3 year total shareholder...
Artificial intelligence is changing the world, but this healthcare technology is quietly doing the same.
Intuitive Surgical Inc. (NASDAQ:ISRG) is one of the best NASDAQ stocks with high upside potential. On May 28, Intuitive announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer, effective July 1. Patton, who has spent nearly two decades at the company, previously led the global endoluminal business, including the successful launch of […]
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Is PRCT a good stock to buy? We came across a bullish thesis on PROCEPT BioRobotics Corporation on r/ValueInvesting by mrmrmrj. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation’s share was trading at $20.91 as of June 17th. Procept BioRobotics (PRCT) is a high-growth surgical robotics company with rapid revenue scaling […]
Intuitive Surgical (NASDAQ:ISRG) is positioned for multi-decade compounding because it sits at the center of an aging-world healthcare megatrend with a razor-and-blade business model that compounds quietly whether the broader market is euphoric or fearful. The case for permanence rests on three pillars, and none of them depend on a single quarter, a single product ... 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 50 Years
Medtronic is deeply undervalued and a good bet for your portfolio. At the time, an uncertain growth outlook kept us from recommending the stock. Four months later, it’s time to retire the narrative of Medtronic as a perpetual laggard.
Due to Baxter International's underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
While Align Technology has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $416.55, marking a +1.34% move from the previous day.
Investors need to pay close attention to (Ticker) stock based on the movements in the options market lately.
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
FDA safety alerts and voluntary recalls tied to Intuitive Surgical stapler reloads have brought fresh regulatory focus to the da Vinci platform. The issues relate to certain da Vinci S and Si instruments and SureForm reloads, with complaints prompting added scrutiny from regulators. Investors have reacted, with NasdaqGS:ISRG down 26.9% year to date and 19.7% over the past year, and the stock last closing at $411.06. This mix of regulatory pressure and weaker recent returns is putting...
Mastercard, Seagate and Intuitive Surgical lead Zacks' featured reports as AI demand, payments growth and procedure expansion shape outlooks.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $412.02 as of June 10th. ISRG’s trailing and forward P/E were 50.06 and 39.68 respectively according to Yahoo […]
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $426.61, indicating a +1.91% shift from the previous trading day.
Intuitive Surgical’s fair value estimate has been reset from US$611.82 to US$565.25, signaling a lower price target that analysts are now using in their models. This shift lines up with recent research that blends optimism about the company’s long term growth potential with caution around weaker medtech sentiment and a reset in sector valuations, leaving opinions on the stock’s risk reward profile divided. As you read on, you will see how this evolving narrative may shape how you track...
Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.